Design of Covalent Nanobodies Containing Latent, Genetically Encoded β-Lactam Amino Acids
ACS Synthetic Biology · 17.11.2026
DOI: 10.1021/acssynbio.6c00683 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Synthetic Biology, online erschienen am 17.11.2026. Verfasst von Zheng Wang und 3 weiteren Autor:innen. Die Arbeit nennt 31 Literaturangaben. Gefördert von: National Institute of General Medical Sciences.
Abstract (Originalsprache)
Owing to their small size, stable immunoglobulin fold, and ease of production, nanobodies have provided versatile tools for biomedical research and an invaluable protein scaffold for biologics development. In conjunction with genetic code expansion, the applications of nanobodies have been extended to covalent nanobodies, nanobody carriers of radiotracers, and PROTAC chimeras. However, the number of genetically encoded crosslinkers suitable for covalent nanobody development remains limited, and latent crosslinkers with enhanced stability and target-specific reactivity are urgently needed. In this work, we report the incorporation of up to three copies of β-lactam-lysine (BeLaK), a genetically encoded latent crosslinker, at the CDR loops of two EGFR-binding nanobodies following a structure-based design and evaluation of their covalent binding to EGFR in vitro and on the cell surface. To improve the crosslinking efficiency, we investigated two parallel strategies: interfacial protein engineering and biparatopic design. Multiple mutations at the binding interface were well tolerated in terms of EGFR binding affinity, and the biparatopic design raised the affinity by 33−44-fold. However, the crosslinking reactivities of covalent nanobodies, including biparatopic nanobodies, were modest, suggesting that the binding affinity and the crosslinking efficiency are not tightly coupled. One exception was a neighboring residue substitution, E44H, which substantially increased the crosslinking yield, highlighting the local chemical environment as a key determinant of BeLaK reactivity. These results reaffirmed the robust substrate properties of BeLaK in genetic code expansion and the high stability of the encoded proteins in biological systems and uncovered a strategy of interfacial engineering to enhance BeLaK’s latent reactivity after initial target binding.
Förderung
- National Institute of General Medical Sciences
Zitieren
APA
Wang, Z., Rabb, J. D., Nabeela, S. A., & Lin, Q. (2026). Design of Covalent Nanobodies Containing Latent, Genetically Encoded β-Lactam Amino Acids. ACS Synthetic Biology. https://doi.org/10.1021/acssynbio.6c00683
Vancouver
Wang Z, Rabb JD, Nabeela SA, Lin Q. Design of Covalent Nanobodies Containing Latent, Genetically Encoded β-Lactam Amino Acids. ACS Synthetic Biology. 2026. doi:10.1021/acssynbio.6c00683
BibTeX
@article{Wang2026,
author = {Wang, Zheng and Rabb, Johnathan D. and Nabeela, Sabreena Aleem and Lin, Qing},
title = {Design of Covalent Nanobodies Containing Latent, Genetically Encoded β-Lactam Amino Acids},
journal = {ACS Synthetic Biology},
year = {2026},
doi = {10.1021/acssynbio.6c00683}
}
EUVIMED